In vitro and in vivo effects of statins on platelet-activating factor and its metabolism

Angiology

Volumn 62, Issue 3, 2011, Pages 209-218

  Tsantila, Nektaria ^a   Tsoupras, Alexandros B ^a   Fragopoulou, Elizabeth ^b   Antonopoulou, Smaragdi ^b   Iatrou, Christos ^c   Demopoulos, Constantinos A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

lyso PAF acetyltransferase; PAF cholinephosphotransferase; plasma PAF acetylhydrolase; platelet activating factor (PAF); simvastatin; statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THROMBOCYTE ACTIVATING FACTOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; LEUKOCYTE; NONHUMAN;

ANIMALS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MESANGIAL CELLS; PLATELET ACTIVATING FACTOR; RABBITS; REPRODUCIBILITY OF RESULTS; SIMVASTATIN; STATISTICS, NONPARAMETRIC;

EID: 79952810812     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710375089     Document Type: Article

References (61)

1. Keaney JFJr. Atherosclerosis from lesion formation to plaque activation and endothelial dysfunction. Molec Aspects Med. 2000 ; 21 (4-5). 99-166.
2. Stocker R., Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004 ; 84 (4). 1381-478. (Pubitemid 39302636)
3. Spady DK Dietary fatty acids and atherosclerosis regression. Br J Nutr. 1999 ; 82 (5). 337-338. (Pubitemid 29531262)
4. Davignon J. Cardioprotective and other emerging effects of statins. Int J Clin Pract. 2004 ; 58: 49-57. (Pubitemid 39627022)
5. Davignon J. Emphasis on pleiotropic effects, a new paradigm shift? Coronary Artery Dis. 2004 ; 15 (5). 223-225. (Pubitemid 39061603)
6. Zhou Z., Rahme E., Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006 ; 151 (2). 273-281. (Pubitemid 43144726)
7. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004 ; 109 (23 suppl 1). 39-43.
8. Ruef J. Interactions of statins with antithrombotic drugs. Medizinische Klinik. 2004 ; 99 (2). 65-70. (Pubitemid 38235194)
9. Pahan K. Lipid-lowering drugs. Cellular and Molecular Life Sci. 2006 ; 63 (10). 1165-1178. (Pubitemid 43939003)
10. Tsoupras AB, Iatrou C., Frangia C., Demopoulos CA The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets. 2009 ; 9 (4). 390-399.
11. Jadhav SB, Jain GK Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol. 2006 ; 58 (1). 3-18. (Pubitemid 43041991)
12. Sterling KA, Tehrani T., Rudnick MR Clinical significance and preventive strategies for contrast-induced nephropathy. Curr Opin Nephrol Hypertens. 2008 ; 17 (6). 616-23.
13. Lindy O., Suomalainen K., Makela M., Lindy S. Statin use is associated with fewer periodontal lesions: a retrospective study. BMC Oral Health. 2008 ; 8: 16.
14. Demopoulos CA, Pinckard RN, Hanahan DJ Platelet-activating factor-evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 ; 254 (19). 9355-9358. (Pubitemid 10248704)
15. Camussi G., Tetta C., Bussolino F., Andres G., Turello E., Baglioni C. Involvement of cytokines and platelet-activating factor in renal pathology. J Lipid Mediat. 1990 ; 2 (suppl): S203 - S213.
16. Montrucchio G., Alloatti G., Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000 ; 80 (4). 1669-1699.
17. Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor-a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003 ; 105: 705-716. (Pubitemid 37533028)
18. Heon Seo K., Ko HM, Kim HA, et al. Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappa B activation. Cancer Res. 2006 ; 66 (9). 4681-4686.
19. Epstein LG, Gelbard, HA HIV-1-induced neuronal injury in the developing brain. J Leukocyte Biol. 1999 ; 65 (4). 453-457. (Pubitemid 29160172)
20. Biancone L., Cantaluppi V., Boccellino M., et al. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. Am J Pathol. 1999 ; 155 (5). 1731-1739.
21. Bussolati B., Biancone L., Cassoni P., et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol. 2000 ; 157 (5). 1713-1725.
22. Alfaro V. Role of histamine and platelet-activating factor in allergic rhinitis. J Physiol Biochem. 2004 ; 60 (2). 101-111.
23. Siesjo BK, Katsura K. Ischemic brain damage: focus on lipids and lipid mediators. Adv Exp Med Biol. 1992 ; 318: 41-56.
24. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM Platelet-activating factor and related lipid mediators. Annu Rev Biochem. 2000 ; 69: 419-445.
25. Snyder F. CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta. 1997 ; 1348 (1-2). 111-116. (Pubitemid 27467083)
26. Francescangeli E., Boila A., Goracci G. Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex. Neurochem Res. 2000 ; 25 (5). 705-713. (Pubitemid 30422005)
27. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci. 2003 ; 40 (6). 643-672. (Pubitemid 37491708)
28. Bate C., Rumbold L., Williams A. Cholesterol synthesis inhibitors protect against platelet-activating factor-induced neuronal damage. J Neuroinflam. 2007 ; 18: 5.
29. Antonopoulou S., Fragopoulou E., Karantonis HC, et al. Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. J Med Food. 2006 ; 9 (3). 356-362. (Pubitemid 44850719)
30. Kaesemeyer WH, Caldwell RB, Huang J., Caldwell RW Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999 ; 33 (1). 234-241. (Pubitemid 29064099)
31. Tsoupras AB, Chini M., Tsogas N., et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection ? AIDS Res Hum Retroviruses. 2008 ; 24 (8). 1079-1086.
32. Tsoupras AB, Fragopoulou E., Nomikos T., Iatrou C., Antonopoulou S., Demopoulos CA Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDTinsensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflam. 2007 ; 2007: 27683.
33. Antonopoulou S., Demopoulos CA, Iatrou C., Moustakas G., Zirogiannis P. Platelet-activating-factor acetylhydrolase (Paf-Ah) in human kidney. Int J Biochem. 1994 ; 26 (9). 1157-1162.
34. Karantonis HC, Antonopoulou S., Perrea DN, et al. In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits. Nutr Metab Cardiovasc Dis. 2006 ; 16 (3). 174-185.
35. Tsantila N., Karantonis HC, Perrea DN, et al. Antithrombotic and antiatherosclerotic properties of olive oil and olive pomace polar extracts in rabbits. Mediators Inflam., 2007 ; 2007: 36204.
36. Tsantila N., Karantonis HC, Perrea DN, et al. Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration. Nutr Metab Cardiovasc Dis. 2009 (In Press).
37. Schnitzer E., Pinchuk I., Bor A., Fainaru M., Samuni AM, Lichtenberg D. Lipid oxidation in unfractionated serum and plasma. Chem Physics Lipids 1998 ; 92 (2). 151-170. (Pubitemid 28327447)
38. Bradford MM A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 ; 72: 248-254.
39. Athyros VG, Kakafika AI, Tziomalos K., Karagiannis A., Mikhailidis DP Pleiotropic effects of statins-clinical evidence. Curr Pharm Des. 2009 ; 15 (5). 479-489.
40. White CM Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol. 1999 ; 39 (2). 111-118. (Pubitemid 29068154)
41. Heuer HO Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists. Lipids. 1991 ; 26 (12). 1369-1373.
42. Fletcher JR, DiSimone AG, Earnest MA Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann Surg 1990 ; 211 (3). 312-316. (Pubitemid 20105984)
43. Izquierdo I., Merlos M., García-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today 2003 ; 39 (6). 451-468.
44. Zanglis A., Lianos EA, Demopoulos CA The biological activity of acetylated sphingosylphosphorylcholine derivatives. Int J Biochem Cell Biol. 1996 ; 28 (1). 63.
45. Tournis S., Demopoulos CA, Siafaka A., et al. Synthesis and biological study of the possible active component of pine pollen. Platelet-Activating Factor. Paper presented at The Second International Conference ; October 26-29, 1986 ; Tennessee, USA.
46. Eisaf M., Tselepis AD Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol. 2003 ; 66 (11). 2069-2073. (Pubitemid 37377852)
47. Carlquist JF, Muhlestein JB, Anderson JL Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn. 2007 ; 7 (5). 511-517. (Pubitemid 47547719)
48. Karabina SA, Ninio E. Plasma PAF-acetylhydrolase: an unfulfilled promise? Biochim Biophys Acta. 2006 ; 1761 (11). 1351-1358.
49. Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta. 2006 ; 1761 (11). 1359-1372. (Pubitemid 44738709)
50. Zhang B., Fan P., Shimoji E., et al. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis. 2006 ; 186 (2). 291-301.
51. Beltowski J., Wojcicka G., Jamroz A. Effect of 3-hydroxy-3- methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J Cardiovasc Pharmacol. 2004 ; 43 (1). 121-127. (Pubitemid 38032073)
52. Tsimihodimos V., Karabina SA, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol. 2002 ; 22 (2). 306-311. (Pubitemid 34127044)
53. Kom G., Schwedhelm E., Maas R., Schneider L., Benndorf R., Böger R. Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F2trans-isoprostane in hypercholesterolaemic patients. Br J Clin Pharmacol. 2007 ; 63 (6). 672-679. (Pubitemid 46753570)
54. Guerra R., Zhao B., Mooser V., Stafforini D., Johnston JM, Cohen JC Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997 ; 38 (11). 2281-2288. (Pubitemid 27495387)
55. Iatrou C., Moustakas G., Antonopoulou S., Demopoulos CA, Zirogiannis P. Platelet-activating factor (PAF) levels and PAF acetylhydrolase (AH) activities in patients with primary glomerulonephritis (PGN). Nephron. 1996 ; 72 (4). 611-616. (Pubitemid 26098261)
56. Satoh K., Imaizumi T., Kawamura Y., et al. Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2. J Clin Invest. 1991 ; 87 (2). 476-481.
57. Wu SC, Shiang JC, Lin SL, et al. Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. Heart Vessels. 2005 ; 20 (5). 217-223.
58. Rosenson RS, Wolff D., Tangney CC Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Clin Sci. 2004 ; 106 (2). 215-217. (Pubitemid 38223440)
59. Serradji N., Bensaid O., Martin M., et al. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication. J Med Chem. 2000 ; 43 (11). 2149-2154. (Pubitemid 30354539)
60. Sirtori CR Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther. 1993 ; 60 (3). 431-459. (Pubitemid 24180170)
61. Fragopoulou E., Iatrou C., Demopoulos CA Characterization of acetyl-CoA: lyso-PAF acetyltransferase of human mesangial cells. Mediators Inflamm. 2005 ; 2005 (5). 263-272. (Pubitemid 41577416)